Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
暂无分享,去创建一个
A. Tordai | Á. Szilágyi | Z. Prohászka | M. Réti | G. Sinkovits | P. Farkas | K. Rázsó | A. Szilvási | D. Inotai
[1] M. Schaller,et al. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome , 2018, Journal of thrombosis and haemostasis : JTH.
[2] I. Koneczny. A New Classification System for IgG4 Autoantibodies , 2018, Front. Immunol..
[3] A. Verkman,et al. Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..
[4] S. Vesely,et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. , 2017, Blood advances.
[5] A. Tordai,et al. The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura. , 2017, Human immunology.
[6] E. Ostertag,et al. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro , 2016, Transfusion.
[7] A. ten Brinke,et al. CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. , 2016, Blood.
[8] M. Scully,et al. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura☆ , 2015, EBioMedicine.
[9] B. Lämmle,et al. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. , 2014, Blood.
[10] S. Ferrari,et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura , 2014, Haematologica.
[11] A. ten Brinke,et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. , 2012, Blood.
[12] D. Consonni,et al. ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura , 2012, Journal of thrombosis and haemostasis : JTH.
[13] I. Scharrer,et al. The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura , 2012, Annals of Hematology.
[14] J. Voorberg,et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain , 2011, Haematologica.
[15] Eric Rondeau,et al. Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience , 2010, PloS one.
[16] É. Azoulay,et al. HLA‐DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency‐related idiopathic thrombotic thrombocytopenic purpura in Caucasians , 2010, Journal of thrombosis and haemostasis : JTH.
[17] S. Vesely,et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. , 2010, Blood.
[18] M. Scully,et al. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link , 2010, Journal of thrombosis and haemostasis : JTH.
[19] J. Mira,et al. HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians. , 2009 .
[20] S. Ferrari,et al. IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.
[21] Z. Prohászka,et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure , 2009, Thrombosis and Haemostasis.
[22] P. Bruhns,et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.
[23] J. Voorberg,et al. VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura , 2009, Journal of thrombosis and haemostasis : JTH.
[24] F. Fabris,et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission , 2008, Haematologica.
[25] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[26] É. Oksenhendler,et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.
[27] J. V. van Mourik,et al. Multiple B‐cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type‐1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.
[28] X. Zheng,et al. Inhibitory autoantibodies against ADAMTS‐13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS‐13 protease and may accelerate its clearance in vivo , 2006, Journal of thrombosis and haemostasis : JTH.
[29] H. Deckmyn,et al. ADAMTS‐13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences , 2006, Journal of thrombosis and haemostasis : JTH.
[30] B. Lämmle,et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. , 2005, Blood.
[31] M. Stephens,et al. Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation , 2022 .
[32] F. Dorner,et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. , 2003, Blood.
[33] G. Hutchins,et al. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. , 2003, Archives of pathology & laboratory medicine.
[34] K. Fujikawa,et al. Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura* , 2001, The Journal of Biological Chemistry.
[35] T. Foroud,et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.
[36] K. Fujikawa,et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. , 2001, Blood.
[37] P. Donnelly,et al. A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.
[38] B. Lämmle,et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.
[39] H. Tsai,et al. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.
[40] B. Lämmle,et al. Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura , 1997 .
[41] M. Neuberger,et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.
[42] R. Aalberse,et al. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. , 1986, Journal of immunology.
[43] R. Aalberse,et al. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. , 1983, Journal of immunology.
[44] D. Deykin,et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.
[45] K. N. Dollman,et al. - 1 , 1743 .